famotidine has been researched along with Carcinoma, Renal Cell in 3 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "High-dose, continuous-infusion interleukin-2 (IL-2) followed by pulse dose and concurrent administration of famotidine has demonstrated response rates of 64% and 33% in patients with metastatic melanoma and metastatic renal cell carcinoma, respectively." | 4.84 | Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine. ( Quan, W; Tyre, CC, 2007) |
| "Famotidine may enhance the LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.40 | Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer. ( Quan, FM; Quan, WD, 2014) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, WD | 2 |
| Quan, FM | 2 |
| Tyre, CC | 1 |
| Quan, W | 1 |
| King, LA | 1 |
| Walker, PR | 1 |
1 review available for famotidine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Drug | 2007 |
2 other studies available for famotidine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2014 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |